TR199802345T2 - Siklooksijenaz-2-aracili hastaliklarda günde bir kez tatbikat için bilesimler. - Google Patents

Siklooksijenaz-2-aracili hastaliklarda günde bir kez tatbikat için bilesimler.

Info

Publication number
TR199802345T2
TR199802345T2 TR1998/02345T TR9802345T TR199802345T2 TR 199802345 T2 TR199802345 T2 TR 199802345T2 TR 1998/02345 T TR1998/02345 T TR 1998/02345T TR 9802345 T TR9802345 T TR 9802345T TR 199802345 T2 TR199802345 T2 TR 199802345T2
Authority
TR
Turkey
Prior art keywords
mediated diseases
cyclooxygenase
once
treatment
compositions
Prior art date
Application number
TR1998/02345T
Other languages
English (en)
Inventor
Hancock Bruno
Winters Conrad
Gertz Barry
Ehrich Elliot
Original Assignee
Merck & Co., Inc.
Merck Frosst Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199802345(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co., Inc., Merck Frosst Canada Inc. filed Critical Merck & Co., Inc.
Publication of TR199802345T2 publication Critical patent/TR199802345T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bu bulus, siklooksijenaz-aracili hastaliklarin tedavisi için bir farmasötik bilesime yöneliktir, bahsedilen bilesim günde bir kez tatbikat için müsaittir, bahsedilen bilesim, siklooksijenaz-1'e tercihan, siklooksijenaz-2'nin engellenmesi için yüksek derecede özgüllük, yüksek kuvvet, uzun bir yari-ömür özelligini tasiyan bir siklooksijenaz-2 engelleyici bilesigi içermektedir. Böyle bir bilesik, 3-fenil-4-(4-metilsülfonil)fenil)-2-(5H)-furanon ile örneklenmektedir. Bu bulus, bir yaninda, siklooksijenaz-2-aracili hastaliklarin tedavisi için bir farmasötik bilesime yöneliktir, bahsedilen bilesim günde bir kez agizdan tatbikat için müsaittir, yukaridaki bilesikten 5-125 mg içermektedir. Bulus, ayni zamanda, siklojenaz-2 aracili hastaliklarin tedavisi için bir yönteme de yöneliktir, bu yöntem, yukaridaki bilesigin 5-125 mg'inin günde bir kez agizdan tatbikini içermektedir. Bulus, siklojenaz-2-aracili hastaliklarin tedavisi için günde bir kez tatbikat için bahsedilen ...(DEVAMI VAR^)
TR1998/02345T 1996-05-17 1997-05-13 Siklooksijenaz-2-aracili hastaliklarda günde bir kez tatbikat için bilesimler. TR199802345T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (1)

Publication Number Publication Date
TR199802345T2 true TR199802345T2 (tr) 1999-03-22

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02345T TR199802345T2 (tr) 1996-05-17 1997-05-13 Siklooksijenaz-2-aracili hastaliklarda günde bir kez tatbikat için bilesimler.

Country Status (29)

Country Link
US (1) US6063811A (tr)
EP (1) EP0910368A1 (tr)
JP (1) JPH11512754A (tr)
KR (1) KR100373622B1 (tr)
CN (1) CN1140267C (tr)
AR (1) AR012014A1 (tr)
AU (1) AU3004997A (tr)
BG (1) BG103000A (tr)
BR (1) BR9709097A (tr)
CA (1) CA2254061C (tr)
CO (1) CO5050370A1 (tr)
CZ (1) CZ291463B6 (tr)
DZ (1) DZ2200A1 (tr)
EA (1) EA001596B1 (tr)
EE (1) EE03746B1 (tr)
HK (1) HK1021623A1 (tr)
HR (1) HRP970262A2 (tr)
HU (1) HUP9902889A3 (tr)
ID (1) ID16921A (tr)
IL (1) IL126899A (tr)
IS (1) IS4891A (tr)
MY (1) MY116201A (tr)
NO (1) NO985342D0 (tr)
NZ (1) NZ332670A (tr)
PE (1) PE66998A1 (tr)
PL (1) PL188649B1 (tr)
SK (1) SK284330B6 (tr)
TR (1) TR199802345T2 (tr)
WO (1) WO1997044028A1 (tr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
JP2002506024A (ja) * 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
MXPA02006150A (es) * 1999-12-22 2004-09-06 Pharmacia Corp Formulaciones de liberacion sostenida de un inhibidor de ciclooxigenasa-2.
RU2003100874A (ru) 2000-06-13 2004-06-27 Вайс (Us) Болеутоляющие и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
ATE329583T1 (de) * 2000-08-18 2006-07-15 Pharmacia Corp Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2002089798A2 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
AP2004002999A0 (en) * 2001-09-26 2004-03-31 Pharmacia Corp Organoleptically acceptable intraorally disintegrating compositions
MXPA04003404A (es) * 2001-10-10 2004-06-18 Pharmacia Corp Composiciones de valdecoxib de disgregacion intraoral preparadas mediante un procedimiento de desecacion por pulverizacion.
KR20040089654A (ko) * 2002-03-07 2004-10-21 노파르티스 아게 약제학적 조성물
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
CA2519189C (en) 2003-05-07 2012-07-17 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
US20200323813A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with cox-2 selective non-steroidal anti-inflammatory drugs
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
EP0739340A1 (en) * 1994-01-10 1996-10-30 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors

Also Published As

Publication number Publication date
PE66998A1 (es) 1998-10-24
KR100373622B1 (ko) 2003-07-12
ID16921A (id) 1997-11-20
HUP9902889A2 (hu) 2002-01-28
EA199801017A1 (ru) 1999-04-29
EE9800393A (et) 1999-06-15
MY116201A (en) 2003-11-28
NO985342L (no) 1998-11-16
DZ2200A1 (fr) 2004-06-20
CN1140267C (zh) 2004-03-03
PL329940A1 (en) 1999-04-26
CZ291463B6 (cs) 2003-03-12
SK156798A3 (en) 2000-01-18
IS4891A (is) 1998-11-10
NZ332670A (en) 2000-07-28
CZ373898A3 (cs) 1999-06-16
SK284330B6 (sk) 2005-01-03
HK1021623A1 (en) 2000-06-23
BR9709097A (pt) 1999-08-03
CA2254061C (en) 2003-12-02
CO5050370A1 (es) 2001-06-27
IL126899A0 (en) 1999-09-22
IL126899A (en) 2004-03-28
CN1225010A (zh) 1999-08-04
JPH11512754A (ja) 1999-11-02
NO985342D0 (no) 1998-11-16
HUP9902889A3 (en) 2002-04-29
EP0910368A1 (en) 1999-04-28
WO1997044028A1 (en) 1997-11-27
PL188649B1 (pl) 2005-03-31
KR20000011082A (ko) 2000-02-25
EE03746B1 (et) 2002-06-17
AU3004997A (en) 1997-12-09
HRP970262A2 (en) 1998-06-30
US6063811A (en) 2000-05-16
CA2254061A1 (en) 1997-11-27
EA001596B1 (ru) 2001-06-25
BG103000A (en) 1999-09-30
AR012014A1 (es) 2000-09-27

Similar Documents

Publication Publication Date Title
TR199802345T2 (tr) Siklooksijenaz-2-aracili hastaliklarda günde bir kez tatbikat için bilesimler.
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
KR940001900A (ko) 환상 유착 억제제
DK0828724T3 (da) 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
PT948527E (pt) Novos derivados de ciclosporina sua preparacao e composicoes farmaceuticas que os contem
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
DK0888111T3 (da) Modified-release-dosispræparat med multiple enheder
HUP0004318A2 (hu) Atorvastatint és egy vérnyomáscsökkentő szert tartalmazó gyógyszerkészítmény
NO983529D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
PT951473E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
NO983530L (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
NO985679D0 (no) Dihydrobenzopyran og beslektede forbindelser nyttige som anti-inflammasjonsmidler
DE69816047D1 (en) (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
BR9502072A (pt) Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica
NO973401L (no) Kortikosteroidinneholdende sammensetninger og fremstilling derav
NO983528D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
ES2116591T3 (es) Cicloalquilhidroxiureas y su uso como inhibidores de la lipoxigenasa.
MY119407A (en) 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor.
ECSP972123A (es) Composiciones para un tratamiento de una sola vez de enfermedades en que intervienen la ciclooxigenasa- 2 -
YU51698A (sh) Farmaceutska kompozicija za lečenje bolesti prouzrokovanih ciklooksigenazom-2 koja sadrži jedinjenje sa dugim vremenom poluraspada koje inhibira cox-2 i upotreba takvog jedinjenja za proizvodnju leka za lečenje bolesti prouzrokovanih ciklooksigenazom-2
GEP20053513B (en) 2-Aminocarbonyl-9H-Purine Derivatives